Estrogen Receptor-positive Breast Cancer

Top drugs studied for this disease

All Approvals Safety alerts Label changes Trial results Research Guidance Withdrawals

CLINICAL_TRIALS withdrawal · 2025-12-24
Clinical Trial Update: Effect of Capivasertib on ctDNA in ER Positive Breast Cancer [Phase 2]
A Phase 2 trial evaluating capivasertib on circulating tumor DNA in estrogen receptor-positive breast cancer has been withdrawn.